<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641653</url>
  </required_header>
  <id_info>
    <org_study_id>0120110037</org_study_id>
    <nct_id>NCT01641653</nct_id>
  </id_info>
  <brief_title>Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period</brief_title>
  <official_title>Does the Administration of Preop Midazolam Assist in Maintaining Blood Glucose Norms in Non-diabetic Patient During the Perioperative Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to investigate if patients who receive a commonly used sedative
      drug, known as midazolam, are likely to have high blood sugar levels during the stressful
      period during and immediately after surgery. A sedative drug is used to relax a person
      without making them sleepy. This drug is also helpful in reducing the memory of the stressful
      experience before the anesthesiologists administers anesthesia. Everyone has glucose or sugar
      in their blood stream. This sugar gives energy to our organs to allow them to work. Since
      high blood sugar levels may be associated with complications like wound infections, the
      investigators research is being done to find if patients who receive a sedative medication
      prior to their surgical procedure have lower blood sugars during the surgery then a patient
      who does not receive the sedation. The investigators would like to know if the administration
      of this commonly used drug will help patients maintain a normal glucose level during a
      stressful period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery performed during general anesthesia induces a stress response partially through a
      catabolic energy state. As a result, serum glucose may rise to levels which have been
      associated with major morbidity and mortality. In patients undergoing cardiac surgery,
      typically &quot;tight glycemic control&quot; strategies are used to prevent hyper- and hypo-glycemia in
      the perioperative period, before the effects of perioperative hyperglycemia begin to emerge.
      In one study a high percentage of patients in the control group had intraoperative blood
      glucose levels over 225. After one hour of surgery: 20%, after two hours: 28%, after three
      hours: 31% and in the post-anesthesia recovery room: 52% of patients. These high levels of
      glucose could be associated with significant post-operative morbidity such as wound infection
      and pneumonia as shown in the cardiac surgery population.

      Glucose alterations induced by psychological stress have been studied in rats but not in
      humans.

      Midazolam is a short acting benzodiazepine that depresses central nervous system. It is
      indicated for anxiolysis, amnesia and sedation. We hypothesize that the administration of
      midazolam may be beneficial in suppressing the catabolic energy state, maintaining normal
      glucose levels during this stressful period. This commonly available inexpensive drug, which
      is tolerated well by the majority of patients, may be useful in maintaining normal glucose
      levels and minimize adverse postoperative outcomes, such as wound and urinary tract
      infections and pneumonia.

      We propose a prospective, single blind (subject only) randomized study to measure glucose
      levels in non diabetic patients undergoing both ventral and inguinal hernia repair. Patients
      scheduled for hernia repair will be approached on the morning of surgery (on E yellow) and
      following the completion of the informed consent process, a preoperative capillary glucose
      reading will be performed via the portable Abbott Freestyleâ„¢ Glucometer. Subjects with a
      preoperative reading of greater than 110 will be excluded from the study. Prior to the
      administration of any medication, we will ask all subjects to complete the State Trait
      Anxiety Inventory for Adults (STAI Form Y-1 and Y-2). This is a research instrument for
      anxiety in adults. It is comprised of 40 questions at a 6th grade reading level. It is
      designed to differentiate between the temporary condition of &quot;state anxiety&quot; and a long term
      personality trait. We will determine whether the subjects' perioperative glucose level
      correlates with the his/her score on the STAI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Perioperative Blood Glucose Level of 30 Minute Interval Measurements</measure>
    <time_frame>every 30 min for duration of surgery</time_frame>
    <description>Non diabetic subjects undergoing hernia repair were randomized into 2 groups. Midazolam vs. placebo. Blood glucose level was monitored preoperatively and following induction of anesthesia at 30 minute intervals perioperatively, and after in the PACU at 30 minutes and 60 minutes following arrival. All readings were performed using the Abbott Freestyle Glucose Monitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Level Percent Change From Pre-op to Maximum Glucose Level</measure>
    <time_frame>Preoperatively, intraoperatively 30 min for duration of surgery</time_frame>
    <description>blood glucose level measured preoperatively, through surgical period and in PACU at 30 min and 60 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Intra-op Blood Glucose Level of 140mg/dL or Less</measure>
    <time_frame>perioperatively</time_frame>
    <description>blood glucose level will be tested perioperatively at 30 minute intervals following induction. All glucose levels will be recorded .midazolam group will maintain a blood glucose level perioperatively of 140mg/dL or less</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hernia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>half of the patients will receive Midazolam 1-2.5mg prior to entering the OR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline 2cc. one dose prior to OR</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>1-2.5 mg</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-diabetic preoperative fasting blood sugar level of 110 mg/dL or less.

        Exclusion Criteria:

          -  Fasting blood sugar &gt; than 110mg/dL

          -  Subjects who are pregnant

          -  Subjects who do not speak English

          -  Subjects who are on steroids prior to admission

          -  Hypersensitivity to midazolam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vasanti Tilak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMDNJ/NJMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <results_first_submitted>October 2, 2014</results_first_submitted>
  <results_first_submitted_qc>October 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2014</results_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nondiabetics undergoing hernia repair.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>6/21/11-8/9/12 preoperative holding area</recruitment_details>
      <pre_assignment_details>Non diabetics with fasting blood sugar &lt; = to 110mg/dL scheduled for an elective hernia repair</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>half of the patients will receive placebo (normal saline 2mL) prior to entering the OR
Normal saline: Normal saline 2cc. one dose prior to OR</description>
        </group>
        <group group_id="P2">
          <title>Midazolam</title>
          <description>half of the patients will receive Midazolam prior to entering the OR
Midazolam: 1-2.5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>non diabetics undergoing hernia repair</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>half of the patients will receive placebo (normal saline) prior to entering the OR
Normal saline: Normal saline 2cc. one dose prior to OR</description>
        </group>
        <group group_id="B2">
          <title>Midazolam</title>
          <description>half of the patients will receive Midazolam prior to entering the OR
Midazolam: 1-2.5 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>participants scheduled for hernia repair were screened and consented, preoperative glucose level was then performed with Abbott Freestyle monitor to insure that fasting glucose level was below or equal to 110mg/dL.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Perioperative Blood Glucose Level of 30 Minute Interval Measurements</title>
        <description>Non diabetic subjects undergoing hernia repair were randomized into 2 groups. Midazolam vs. placebo. Blood glucose level was monitored preoperatively and following induction of anesthesia at 30 minute intervals perioperatively, and after in the PACU at 30 minutes and 60 minutes following arrival. All readings were performed using the Abbott Freestyle Glucose Monitor.</description>
        <time_frame>every 30 min for duration of surgery</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline: Normal saline 2cc. IV one dose prior to OR</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>One half of subjects will recieveMidazolam: 1-2.5 mg IV</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Perioperative Blood Glucose Level of 30 Minute Interval Measurements</title>
          <description>Non diabetic subjects undergoing hernia repair were randomized into 2 groups. Midazolam vs. placebo. Blood glucose level was monitored preoperatively and following induction of anesthesia at 30 minute intervals perioperatively, and after in the PACU at 30 minutes and 60 minutes following arrival. All readings were performed using the Abbott Freestyle Glucose Monitor.</description>
          <population>per protocol</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.0" lower_limit="101.0" upper_limit="126.0"/>
                    <measurement group_id="O2" value="108.0" lower_limit="101.0" upper_limit="125.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a pilot study no power calculation was performed. The Wilcoxon rank-sum test was used to assess differences in max intraop glucose between placebo and midazolam groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Level Percent Change From Pre-op to Maximum Glucose Level</title>
        <description>blood glucose level measured preoperatively, through surgical period and in PACU at 30 min and 60 min</description>
        <time_frame>Preoperatively, intraoperatively 30 min for duration of surgery</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline: Normal saline 2cc. IV one dose prior to OR</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>half of subjects will receive Midazolam: 1-2.5 mgIV prior to entering the OR</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Level Percent Change From Pre-op to Maximum Glucose Level</title>
          <description>blood glucose level measured preoperatively, through surgical period and in PACU at 30 min and 60 min</description>
          <population>per protocol</population>
          <units>percentage of increase in glucose level</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" lower_limit="10.99" upper_limit="38.10"/>
                    <measurement group_id="O2" value="14.9" lower_limit="7.69" upper_limit="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>percent change in glucose levels from preoperative level to maximum perioperative measurement level</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>10</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Intra-op Blood Glucose Level of 140mg/dL or Less</title>
        <description>blood glucose level will be tested perioperatively at 30 minute intervals following induction. All glucose levels will be recorded .midazolam group will maintain a blood glucose level perioperatively of 140mg/dL or less</description>
        <time_frame>perioperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>subjects will receive 2cc. Normal Saline prior to entering the OR</description>
          </group>
          <group group_id="O2">
            <title>Midazolam</title>
            <description>subjects will receive midazolam 1.5-2mg prior to entering the OR</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Intra-op Blood Glucose Level of 140mg/dL or Less</title>
          <description>blood glucose level will be tested perioperatively at 30 minute intervals following induction. All glucose levels will be recorded .midazolam group will maintain a blood glucose level perioperatively of 140mg/dL or less</description>
          <units>percentage of glucose levels&lt;140</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>Chi-square with continuity correction</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>half of the patients will receive placebo (normal saline) prior to entering the OR
Normal saline: Normal saline 2cc. one dose prior to OR</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>half of the patients will receive Midazolam prior to entering the OR
Midazolam: 1-2.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vasanti Tilak, MD</name_or_title>
      <organization>Rutgers-New Jersey Medical School</organization>
      <phone>973 972-7477</phone>
      <email>tilakva@njms.rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

